SOX2 and neoplasm: Actinomycin D (ActD) is an FDA-approved NCI oncology drug that specifically targets and downregulates the stem cell transcription factor SRY (sex determining region Y)-Box 2 (SOX2), which leads to stem cell depletion within the tumor bulk [8].